Skip to content
ppharmaranks
Menu
Class IIIOngoing

Estradiol Transdermal System recall

FDA recall D-0542-2024 · initiated May 16, 2024

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jun 12, 2024How we research

Zydus Pharmaceuticals (USA) Inc recalled Estradiol Transdermal System in May 2024 — an FDA Class III recall (D-0542-2024) because Failed Impurities/Degradation Specifications.

Unlikely to cause harm but violates FDA labeling or manufacturing regulations.

Why it was recalled

Failed Impurities/Degradation Specifications.

An impurity above the accepted limit

A by-product of manufacturing or storage exceeded the limit the FDA accepts. Nitrosamines are the common example: the concern is long-term exposure, not immediate danger from one dose.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: M310493, Exp. Date 01/2025; M308397, Exp. Date 11/2024; M305337, Exp. Date 10/2024; M400155, Exp. Date 06/2025; M314660, Exp. Date 05/2025

Quantity recalled: 21,360 units

Details

Product
Estradiol Transdermal System, USP (Twice-Weekly) 0.0375mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1192-8
Recalling company
Zydus Pharms
Classification
Class III
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide within the United States
Initiated
May 16, 2024
FDA report date
Jun 12, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Estradiol Transdermal System recalled?
Zydus Pharmaceuticals (USA) Inc recalled Estradiol Transdermal System in May 2024 — an FDA Class III recall (D-0542-2024) because Failed Impurities/Degradation Specifications. Unlikely to cause harm but violates FDA labeling or manufacturing regulations.
Why was Estradiol Transdermal System recalled?
Per the FDA enforcement record, the reason for recall D-0542-2024 was: Failed Impurities/Degradation Specifications.
Is a recalled Estradiol Transdermal System dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. Unlikely to cause harm but violates FDA labeling or manufacturing regulations. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Estradiol Transdermal System are affected?
Distributed: Nationwide within the United States. The recall covers these lots — Lot #: M310493, Exp. Date 01/2025; M308397, Exp. Date 11/2024; M305337, Exp. Date 10/2024; M400155, Exp. Date 06/2025; M314660, Exp. Date 05/2025. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0542-2024.

Source: openFDA Drug Enforcement record D-0542-2024

← All drug recalls